LD50, rat: >2000 mg/kg. The most common adverse reaction reported in 2% of patients treated with besifloxacin was conjunctival redness.
Besifloxacin is a fourth generation fluoroquinolone-type opthalmic antibiotic for the treatment of bacterial conjunctivitis. FDA approved on May 28, 2009.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Trazodone | The risk or severity of QTc prolongation can be increased when Trazodone is combined with Besifloxacin. |
| Pitolisant | Besifloxacin may increase the QTc-prolonging activities of Pitolisant. |
| Lefamulin | Lefamulin may increase the QTc-prolonging activities of Besifloxacin. |
| Hydroxyzine | The risk or severity of QTc prolongation can be increased when Besifloxacin is combined with Hydroxyzine. |
| Ziprasidone | The risk or severity of QTc prolongation can be increased when Besifloxacin is combined with Ziprasidone. |
| Magnesium | Magnesium can cause a decrease in the absorption of Besifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Haloperidol | The risk or severity of QTc prolongation can be increased when Besifloxacin is combined with Haloperidol. |
| Vibrio cholerae CVD 103-HgR strain live antigen | The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Besifloxacin. |
| Fluoxetine | The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Besifloxacin. |
| Ponesimod | The risk or severity of bradycardia can be increased when Ponesimod is combined with Besifloxacin. |
| Amisulpride | The risk or severity of QTc prolongation can be increased when Besifloxacin is combined with Amisulpride. |
| Estetrol | The therapeutic efficacy of Estetrol can be decreased when used in combination with Besifloxacin. |
| Fexinidazole | The risk or severity of adverse effects can be increased when Besifloxacin is combined with Fexinidazole. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Besifloxacin is combined with Lidocaine. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Besifloxacin is combined with Ropivacaine. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Besifloxacin is combined with Bupivacaine. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Besifloxacin is combined with Cinchocaine. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Besifloxacin is combined with Dyclonine. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Besifloxacin is combined with Procaine. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Besifloxacin is combined with Prilocaine. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Besifloxacin is combined with Proparacaine. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Besifloxacin is combined with Meloxicam. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Besifloxacin is combined with Oxybuprocaine. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Besifloxacin is combined with Cocaine. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Besifloxacin is combined with Mepivacaine. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Besifloxacin is combined with Levobupivacaine. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Besifloxacin is combined with Diphenhydramine. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Besifloxacin is combined with Benzocaine. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Besifloxacin is combined with Chloroprocaine. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Besifloxacin is combined with Phenol. |
| Tetrodotoxin | The risk or severity of methemoglobinemia can be increased when Besifloxacin is combined with Tetrodotoxin. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Besifloxacin is combined with Benzyl alcohol. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Besifloxacin is combined with Capsaicin. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Besifloxacin is combined with Etidocaine. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Besifloxacin is combined with Articaine. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when Besifloxacin is combined with Tetracaine. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Besifloxacin is combined with Propoxycaine. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Besifloxacin is combined with Pramocaine. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Besifloxacin is combined with Butamben. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Besifloxacin is combined with Butacaine. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Besifloxacin is combined with Oxetacaine. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Besifloxacin is combined with Ethyl chloride. |
| Butanilicaine | The risk or severity of methemoglobinemia can be increased when Besifloxacin is combined with Butanilicaine. |
| Metabutethamine | The risk or severity of methemoglobinemia can be increased when Besifloxacin is combined with Metabutethamine. |
| Quinisocaine | The risk or severity of methemoglobinemia can be increased when Besifloxacin is combined with Quinisocaine. |
| Cisatracurium | Besifloxacin may increase the neuromuscular blocking activities of Cisatracurium. |
| Clozapine | The risk or severity of QTc prolongation can be increased when Besifloxacin is combined with Clozapine. |
| Glasdegib | The risk or severity of QTc prolongation can be increased when Besifloxacin is combined with Glasdegib. |
| Ambroxol | The risk or severity of methemoglobinemia can be increased when Besifloxacin is combined with Ambroxol. |
| Fezolinetant | The serum concentration of Fezolinetant can be increased when it is combined with Besifloxacin. |
| Fecal microbiota | The therapeutic efficacy of Fecal microbiota can be decreased when used in combination with Besifloxacin. |
| Vilanterol | The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Besifloxacin. |
| Oxaliplatin | The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Besifloxacin. |
| Quizartinib | The risk or severity of QTc prolongation can be increased when Besifloxacin is combined with Quizartinib. |
| Citalopram | The risk or severity of QTc prolongation can be increased when Besifloxacin is combined with Citalopram. |
| Pimavanserin | The risk or severity of QTc prolongation can be increased when Besifloxacin is combined with Pimavanserin. |
| Gepirone | The risk or severity of QTc prolongation can be increased when Gepirone is combined with Besifloxacin. |
| Etrasimod | The risk or severity of QTc prolongation and torsade de pointes can be increased when Etrasimod is combined with Besifloxacin. |
| Bedaquiline | The risk or severity of QTc prolongation can be increased when Besifloxacin is combined with Bedaquiline. |
| Encorafenib | The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Besifloxacin. |
| Givinostat | The risk or severity of QTc prolongation can be increased when Besifloxacin is combined with Givinostat. |
| Inotuzumab ozogamicin | The risk or severity of QTc prolongation can be increased when Besifloxacin is combined with Inotuzumab ozogamicin. |
| Mavorixafor | The risk or severity of QTc prolongation can be increased when Mavorixafor is combined with Besifloxacin. |
| Ribociclib | The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Besifloxacin. |
| Revumenib | The risk or severity of QTc prolongation can be increased when Besifloxacin is combined with Revumenib. |